Form 4: ClearPoint Neuro CBO Acquires Stock via ESPP

ClearPoint Neuro's Chief Business Officer, L. Jeremy Stigall, acquired one share of common stock through the company's Employee Stock Purchase Plan at $9.57 per share.

Summary

• L. Jeremy Stigall, Chief Business Officer of ClearPoint Neuro, Inc. (CLPT), acquired common stock.
• The acquisition occurred on December 31, 2025.
• One share of common stock was acquired at a price of $9.57 per share.
• The transaction was made pursuant to the Employee Stock Purchase Plan (ESPP) for the purchase period of July 1, 2025, through December 31, 2025.
• Shares were purchased at the lesser of 85% of the fair market value on either the first day or last day of the purchase period.
• Following this transaction, Mr. Stigall beneficially owns 72,356 shares of common stock.

Sentiment

Score: 6

Explanation: The acquisition of shares by a Chief Business Officer, even a small amount, through an ESPP is generally viewed as a positive signal of management's alignment with shareholder interests and confidence in the company's valuation.

Positives

• Officer L. Jeremy Stigall's participation in the Employee Stock Purchase Plan demonstrates alignment with shareholder interests.
• The acquisition of shares, even a small amount, indicates confidence in the company's future.

Negatives

• The acquisition of only one share of common stock, while part of an ESPP, represents a minimal direct investment by the Chief Business Officer.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Potential positive signal of insider confidence, though minimal due to the small number of shares.
• Employees: Reinforces the existence and use of employee benefit programs like the ESPP.

Key Dates

Recommendation

This Form 4 filing reports a routine, small-scale acquisition of common stock by a Chief Business Officer through an Employee Stock Purchase Plan. While insider buying can be a positive signal, the minimal number of shares acquired (1 share) does not provide sufficient new information to warrant a change in investment recommendation. Investors should consider broader financial performance and strategic developments for investment decisions.

Keywords

ClearPoint Neuro, CLPT, Form 4, insider transaction, stock acquisition, ESPP, employee stock purchase plan, L. Jeremy Stigall